Compare IQIYI Inc - ADR (IQ) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs ResMed Inc. — how do they compare? IQIYI Inc - ADR trades at $1.24 (market cap $1.20B), while ResMed Inc. trades at $195.37 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 24× IQIYI Inc - ADR's market cap, and ResMed Inc. pays a 1.21% dividend while IQIYI Inc - ADR pays none. Which is the better fit depends on your goals.
| IQ | RMD | |
|---|---|---|
Market Cap | $1.20B | $28.81B |
Sector | Media | Health |
52-Week High | $2.79 | $293.73 |
52-Week Low | $0.96 | $182.82 |
Enterprise Value | $2.76B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ stock trades at $1.235, up 3.78% today, with a bullish technical signal and mixed fundamentals. Revenue declined to $27.29B in 2025 with a net loss of $206.31M, but valuation ratios like P/S of 0.3 and P/B of 0.6 appear low. Recent news highlights AI initiatives and leadership changes, while analyst consensus is split with 50% buy ratings.
The outlook is cautious due to profitability challenges and projected revenue decline in 2026, but low valuations and AI-driven content strategy offer potential upside. Key risks include competitive pressures in streaming and regulatory uncertainty in China.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
